Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 431 results for "erbitux"

Erbitux -Drug Insights, 2016

Drug Report, Erbitux- Drug Insights, 2016 highlights the Erbitux marketed details, pipeline status and the Global API Manufacturers along with the location. The report covers the Global Market Assessment of the Erbitux covering the total sales ... Research and Markets, 3 days ago
Erbitux-Drug Insights,2014 Research and Markets, 1 month ago

2 images for "erbitux"

Medagadget.com, 3 days ago
Medagadget.com, 1 week ago
Good Health Suite

Merck's Erbitux approved for NHS Wales

The All Wales Medicines Strategy Group has recommended Merck's Erbitux in combination with chemotherapy for restricted use in the NHS in Wales. Erbitux (cetuximab) is recommended for the first-line treatment of patients with RAS wild-type ...
 Pharmafile1 month ago Latest approvals for use of medicines in Scotland and Wales announced  Good Health Suite3 weeks ago Cetuximab gets go ahead in Wales for mCRC patients  Pharma Letter1 month ago
Mr Top Step

Eli Lilly and Co.'s 4Q15 Earnings: An Overview

Eli Lilly and Co.'s 4Q15 Earnings Showed Growth of ~5% A look at Eli Lilly and Co. On January 28, 2016, Eli Lilly and Co. (LLY) reported an increase in its top line by ~5% in its 4Q15 earnings. The company met Wall Street analysts 4Q15 estimates ...
 Yahoo! Finance2 days ago Eli Lilly and Co.'s 4Q15 Business Segment Performance  Yahoo! Finance3 hours ago Eli Lilly net profit moves up by 12% in Q4  PharmaBiz1 week ago Eli Lilly meets fourth-quarter expectations but trims '16 forecast  MyInforms1 week ago

Single-lesion biopsy may be insufficient to choose therapy targeting resistance mutations

EurekAlert! provides embargoed and breaking science news you can't afford to miss. EurekAlert! offers a one-stop science news distribution service you can trust. EurekAlert! is a service of the American Association for the Advancement of Science. ...
 EurekAlert!23 hours ago

Positive phase III results for cetuximab and infliximab copy biologicals

US-based biopharmaceutical company Sorrento Therapeutics (Sorrento) announced on 11 January 2016 that its partner, MabTech had successfully completed phase III clinical trials in China for STI-001, a copy biological for cetuximab (Erbitux) and ...
 GaBi Online1 day ago SORRENTO THERAPEUTICS : Announces Positive Data from Phase 3 studies of Biosimilar Antibodies, STI-001 and STI-002  4 Traders2 weeks ago Sorrento's RA biosimilar candidates successful in Phase III20-01-2016  Pharma Letter2 weeks ago Sorrento Announces Positive Data from Phase 3 studies of Biosimilar Antibodies, STI-001 and STI-002  Financial Content3 weeks ago
[x]  

Using Glycosidases to Remove, Trim, or Modify Glycans on Therapeutic Proteins

One of the most common posttranslational modifications of eukaryotic proteins is glycosylation. Glycosylation of proteins can affect many biological activities. For therapeutic glycoproteins, it can modify biological activity, targeting, ...
 BioProcess International1 day ago

World Cancer Day: Compulsory licensing of key drugs only way for India to fight this grave threat

Last year, over a million people in India were diagnosed with cancer. In the next 10 years, this number is expected to increase five times. The situation is not just alarming but frightening. As the world on Thursday observes Cancer Day, India needs ...
 Firstpost.com2 days ago

MOLECULAR PARTNERS : reports unaudited financial results for 2015: A year of substantial clinical progress in oncology

AD-HOC RELEASE Molecular Partners reports unaudited financial results for 2015: A year of substantial clinical progress in oncology R&D, Partnership and Team Highlights: Significant advancement of the company's proprietary pipeline in oncology, ...
 4 Traders2 days ago Molecular Partners reports unaudited financial results for 2015: A year of substantial clinical progress in oncology  4 Traders2 days ago

Waksal's latest biotech play is reportedly trying to go public after two misfires

Kadmon founder Sam Waksal Kadmon , a biotech founded by once-jailed ImClone CEO Sam Waksal , is gearing up to test the waters for an IPO, according to CNBC , braving a brutal climate for drug developers on Wall Street after at least two previous ...
 FierceBiotech3 days ago Waksal's Kadmon said to plan IPO, without Waksal  CNBC3 days ago

Wall Street Is as Bearish as 2009: 4 Top Dividend Stocks to Buy Right Now

Source: Wikimedia CommonsIf you remember the dark days of 2009, then it may surprise you to know that currently Wall Street strategists and those who prognosticate the future are as bearish as they were then. In a new research note from Merrill ...
 24/7 Wall St4 days ago Merrill Lynch US 1 List On Sale: 4 Top Dividend Stocks to Buy Now  24/7 Wall St1 week ago Merrill Lynch US 1 List Has 4 Top-Yielding Dividend Stocks to Buy  24/7 Wall St1 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - erbitux
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less